- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04601181
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22 in Patients With Refractory or Relapsed B Cell Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The patients will receive infusion of ThisCART22 cells from health donor ,to evaluate the safety and efficacy of ThisCART22 Cells in patients with refractory or relapsed CD22-positive B cell malignancies.
In this study, the dose range is 0.2-60 x10^6 cells per kg body weight (no more than 3.0 x 10^9 in total).
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Xingbing Wang, M.D.
- Phone Number: +8613856007984
- Email: wangxingbing@ustc.edu.cn
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Recruiting
- The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
-
Contact:
- Xingbing Wang, M.D.
- Phone Number: +8613856007984
- Email: wangxingbing@ustc.edu.cn
-
Contact:
- Jun Li, Ph.D.
- Phone Number: +8618662604088
- Email: jli@ctigen.com
-
Principal Investigator:
- Xingbing Wang, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who volunteered to participate in the research and signed a written informed consent;
- The informed consent was signed between the ages of 3-70, regardless of gender or race;
- CD22 positive hematologic malignancies with no alternative treatment options deemed by investigator. including those who are not eligible for allogeneic stem cell transplantation (SCT) due to the following reasons: 3.1 age; 3.2 Concurrent disease; 3.3 Other contraindications, such as contraindications to total body irradiation (TBI) (TBI is one of the important treatment measures before allogeneic stem cell transplantation of ALL); 3.4 Lack of suitable donors; 3.5 Patients with relapse after CD19-CAR T treatment;
- Estimated life expectancy > 12 weeks deemed by investigator
- Recurrence after any stem cell transplantation (regardless of previous treatment regimen);
Patients who relapse after previous allogeneic SCT (myeloablative or non-myeloablative) and meet all the following entry criteria:
6.1 No active GVHD and no immunosuppression is required; 6.2 Transplant for more than 4 months;
- Serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl;
- Serum ALT/ AST < 5 upper limit of normal (ULN);
- Measurable or detectable disease at time of enrollment,include minimal residual disease (MRD) detected by immunotyping, cytogenetics or PCR.
- Cardiac ejection fraction ≥ 40%.
- Eastern cooperative oncology group (ECOG) performance status of ≤ 2.
- Female subjects with fertility have a negative pregnancy test result within 48 hours before the infusion and are not breast-feeding; all subjects with fertility potential before being enrolled in the study and throughout the study period until the last infusion Within 3 months, take adequate contraceptive measures.
Exclusion Criteria:
- Pregnant or lactating women;
- Participated in another clinical trial during the first 4 weeks of the enrolled study or intended to participate in another clinical trial throughout the study period;
- Have been treated with any gene product;
- Uncontrolled infection;
- History of HIV infection;
- Active hepatitis B virus or hepatitis C virus infection;
- Systemic steroid therapy may be required for cell infusion or collection, or there may be conditions that the investigator considers may require steroid therapy during blood collection or infusion.Corticosteroids for disease treatment are permitted, and inhaled steroids or hydrocortisone physiologic replacement therapy for patients with adrenocortical dysfunction is permitted beyond the time of cell collection or infusion;
- Patients with grade 2-4 GVHD, or deemed need to manage by investigator;
- The presence of GVHD under treatment;.
- Patients with active CNS involvement by malignancy;
- Patients combine with other disease cause neutrophil count (ANC) <750/uL or PLT< 50,000/uL
- The researchers considered the subjects unsuitable for this clinical trial for various reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ThisCART22 cells injection
In this arm,allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
|
Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10^6 CAR-T cells per kg body weight. Intervention study |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of AE or SAE of CART cell infusion in relation to the study drug at grade ≥3 (refer to CTCAE version 4.03);
Time Frame: From infusion to week 12
|
From infusion to week 12
|
ORR (sum of CR and CRi) after infusion.
Time Frame: From infusion to week 12
|
From infusion to week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The survival time of CAR-T-22 cells in vivo;
Time Frame: From infusion to month 12
|
From infusion to month 12
|
ORR at week 4, 8, and 24 after infusion (ORR4, ORR8, ORR24).
Time Frame: At week 4, 8, and 24 after infusion
|
At week 4, 8, and 24 after infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xingbing Wang, M.D., The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ThisCART22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B Cell Malignancy
-
Hebei Yanda Ludaopei HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.; Avalon GloboCare Corp.Completed
-
Fundamenta Therapeutics, Ltd.Anhui Provincial HospitalRecruitingB Cell MalignancyChina
-
Hebei Yanda Ludaopei HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.CompletedB Cell MalignancyChina
-
EdiGene (GuangZhou) Inc.The First Affiliated Hospital of Henan University of Science and TechnologyActive, not recruitingRelapsed or Refractory B-cell Malignancy(NHL/ALL)China
-
Shanghai Longyao Biotechnology Inc., Ltd.Xuzhou Medical University; Shanghai Jiao Tong University School of MedicineUnknownRecurrent or Refractory B Cell MalignancyChina
-
Fundamenta Therapeutics, Ltd.The Affiliated Hospital of Xuzhou Medical UniversityRecruitingB-cell MalignancyChina
-
Fundamenta Therapeutics, Ltd.The Affiliated Hospital of Xuzhou Medical UniversityRecruitingB-cell MalignancyChina
-
Shanghai Tong Ren HospitalGracell Biotechnology Ltd.UnknownB-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic LeukaemiaChina
-
CRISPR Therapeutics AGActive, not recruitingB-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALLUnited States, Spain, Canada, France, Germany, Australia
-
Ohio State University Comprehensive Cancer CenterCompletedIndolent or Intermediate Grade B-cell MalignancyUnited States
Clinical Trials on ThisCART22 cells injection
-
Fundamenta Therapeutics, Ltd.The Affiliated Hospital of Xuzhou Medical UniversityRecruitingB-cell MalignancyChina
-
Ruijin HospitalShanghai Essight Bio Co.,LtdRecruiting
-
MD Stem CellsUnknownGlaucoma | Macular Degeneration | Retinal Disease | Hereditary Retinal Dystrophy | Optic Nerve DiseaseUnited States
-
Yan'an Affiliated Hospital of Kunming Medical UniversityKAEDIUnknownB Cell Lymphoma | B-cell Acute Lymphoblastic LeukemiaChina
-
Chinese PLA General HospitalUnknownLeft Ventricular Dysfunction | Chronic Myocardial Ischemia | Old Myocardial InfarctionChina
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
Wuhan Union Hospital, ChinaRecruiting
-
Royan InstituteCompletedOsteonecrosisIran, Islamic Republic of
-
King Edward Medical UniversityCompleted